Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs 1,112

Quick answer

Infectious disease: NovaPharmaNews indexes 1,112 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

Pipeline programs

Page 7 of 24

  1. interferon alfa

    Ultragenyx UK Limited

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  2. mRNA1647-P301

    Moderna Biotech Spain

    Cytomegalovirus Infection (CMV)

    phase 3 small molecule active

    1 trial

  3. maribavir

    Takeda

    Cytomegalovirus Infections

    phase 3 small molecule completed

    2 trials

  4. mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID

    phase 3 small molecule completed

    1 trial

  5. methadone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 small molecule completed

    1 trial

  6. peginterferon alfa-2a

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 3 small molecule completed

    2 trials

  7. peginterferon alfa-2b (SCH 54031)

    Universal Integrated

    Hepatitis C, Chronic

    phase 3 mab completed

    1 trial

  8. probiotic strain Bb-12

    United Therapeutics Europe Ltd

    Infections, Respiratory

    phase 3 other completed

    1 trial

  9. sotrovimab

    Vir Biotechnology

    Covid19

    phase 3 mab terminated

    3 trials

  10. strengths-based case management

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  11. telbivudine or lamivudine

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

  12. tigecycline

    Wyeth is now a wholly owned subsidiary of Pfizer

    Community-Acquired Infections

    phase 3 small molecule completed

    1 trial

  13. vitamin D

    Takeda

    COVID-19

    phase 3 other completed

    1 trial

  14. -

    The George Institute

    Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT

    phase 2 small molecule active

    1 trial

  15. 1% tenofovir gel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  16. 1.6

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  17. 100U EV71 vaccine with adjuvant

    Sinovac Research and Development Co.,

    Infection, Viral, Enterovirus

    phase 2 mab completed

    1 trial

  18. 16mg，KB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sepsis

    phase 2 small molecule active

    1 trial

  19. 2026-525211-14-00

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  20. 206882

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  21. 212580

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  22. 217043

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  23. 218307

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  24. 219231

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  25. 222638

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  26. 224083

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  27. 400 U EV71 vaccine with adjuvant

    Sinovac Research and Development Co.,

    Infection, Viral, Enterovirus

    phase 2 mab terminated

    1 trial

  28. 413ABM

    BRIGHT MINDS BIOSCIENCES INC.

    MALARIA

    phase 2 other completed

    1 trial

  29. 5 mg/kg CM-101

    Chemomab Therapeutics

    Nonalcoholic Steatohepatitis

    phase 2 mab completed

    1 trial

  30. 5% Nu-3 gel

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infection

    phase 2 small molecule active

    1 trial

  31. 851B

    Takeda

    Papillomavirus Infections

    phase 2 small molecule terminated

    2 trials

  32. AB-729

    Arbutus Biopharma Corp

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  33. AB-729-203

    Arbutus Biopharma Corp

    Chronic HBV Infection

    phase 2 small molecule active

    1 trial

  34. ABI-H0731

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 2 small molecule terminated

    6 trials

  35. ACE393

    Fulcrum Therapeutics

    Campylobacter Infection

    phase 2 mab active

    1 trial

  36. ACT-20-MSC

    Aspire Biopharma Holdings

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  37. ADX-629

    Aldeyra Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  38. ADX-629

    Aldeyra Therapeutics

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial

  39. AK0529

    Shanghai University of Traditional Chinese Medicine

    RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

    phase 2 small molecule completed

    1 trial

  40. AL-335

    Janssen Cilag International NV

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  41. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B Infection

    phase 2 small molecule active

    1 trial

  42. ALG-000184-202

    Aligos Therapeutics

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  43. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  44. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

  45. ANAKINRA

    AXIM BIOTECHNOLOGIES, INC.

    Hyperinflammation, Sepsis

    phase 2 small molecule active

    1 trial

  46. APHP210084

    Pari Pharma GmbH

    first suspected infection with Mycobacterium tuberculosis in the lungs

    phase 2 small molecule active

    1 trial

  47. APHP230848

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  48. APHP240923

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,112 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.